Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class

JAAD Int. 2023 May 26:12:136-138. doi: 10.1016/j.jdin.2023.05.006. eCollection 2023 Sep.

Ahmed Bagit¹, Khalad Maliyar², Jorge R Georgakopoulos², Brian Rankin³, Alexander Rimke⁴, Asfandyar Mufti^{2

5}, Heather Le⁶, Ronald Vender⁶, Vimal H Prajapati^{3

4

7

8

9

10}, Jensen Yeung^{2

5

10

11}

¹ Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
² Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada.
³ Division of Dermatology, Department of Medicine, University of Calgary, Alberta, Canada.
⁴ Dermatology Research Institute, Calgary, Alberta, Canada.
⁵ Division of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
⁶ Dermatrials Research Inc. and Venderm Consulting, Hamilton, Ontario, Canada.
⁷ Section of Community Pediatrics, University of Calgary, Calgary, Alberta, Canada.
⁸ Section of Pediatric Rheumatology, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
⁹ Skin Health & Wellness Centre, Calgary, Alberta, Canada.
¹⁰ Probity Medical Research, Calgary, Alberta, Canada.
¹¹ Division of Dermatology, Women's College Hospital, Toronto, Ontario, Canada.

No abstract available

Keywords: IL-23 inhibitor; biologic; efficacy; guselkumab; psoriasis; risankizumab; safety.